Skip to main content
. 2023 Mar 29;14:1111430. doi: 10.3389/fendo.2023.1111430

Table 1.

Patient and trial characteristics of the included studies.

Study N Intervention, dose Comparator(s) Duration Diabetes or prediabetes NASH or NAFLD Country NASH/NAFLD assessment in results
Aithal (36), 74 Pioglitazone, 30 mg/day Placebo 12 months No NASH United Kingdom Histology
Anushiravani (37), 60 a Lifestyle + pioglitazone, 15 mg/day Lifestyle + placebo 3 months No NAFLD Iran Ultrasound
Sanyal (38), 163 a Pioglitazone, 30 mg/day Placebo 24 months No NASH America Histology
Belfort (11), 47 a Hypocaloric diet + pioglitazone, 45 mg/day Hypocaloric diet + placebo 6 months Yes NASH America Histology
Cusi (12), 101 Pioglitazone, 45 mg/day Placebo 18 months Yes NASH America Histology
Kamolvisit (39), 98 Pioglitazone, 45 mg/day Placebo 18 months Yes NAFLD Thailand Ultrasound
Chehrehgosha (40), 71 a Pioglitazone, 30 mg/day Placebo 6 months Yes NAFLD Iran Ultrasound
a

Represents patients in the trial arms of interest only.